X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
LYL845 is an investigational autologous TIL product enhanced with Epi-R manufacturing protocols for patients with relapsed and/or refractory metastatic or locally advanced melanoma, NSCLC and CRC.
Lead Product(s): LYL845
Therapeutic Area: Oncology Product Name: LYL845
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2023
Details:
LYL845 is an investigational tumor infiltrating lymphocyte (TIL) therapy enhanced with Lyell’s Epi-R™ technology for patients with relapsed and/or refractory metastatic or locally advanced melanoma and other select solid tumors.
Lead Product(s): LYL845
Therapeutic Area: Oncology Product Name: LYL845
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
LYL845 is Lyell’s autologous tumor infiltrating lymphocyte (TIL) product candidate enhanced via Epi-R™, a proprietary epigenetic reprogramming technology, designed to create products with higher proportions of stem-like T cells.
Lead Product(s): LYL845
Therapeutic Area: Oncology Product Name: LYL845
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
LYL797 is an investigational chimeric antigen receptor (CAR) T-cell therapy for patients with receptor tyrosine kinase-like orphan receptor 1-positive (ROR1+) solid tumors.
Lead Product(s): LYL797
Therapeutic Area: Oncology Product Name: LYL797
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
GSK4427296 (LYL132) an investigational T-cell receptor, incorporates Epi-R reprogramming technology and is under investigation as a potential next-generation enhancement to letetresgene autoleucel for patients with solid tumors.
Lead Product(s): LYL132,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: GSK4427296
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
LYL797 is an investigational chimeric antigen receptor (CAR) T-cell therapy for patients with receptor tyrosine kinase-like orphan receptor 1-positive (ROR1+) solid tumors. The presentation will highlight the preclinical data characterizing LYL797.
Lead Product(s): LYL797
Therapeutic Area: Oncology Product Name: LYL797
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
The partnership promotes complementary scientific technologies to develop next generation cell-based therapies for patients with solid cancers.
Lead Product(s): T cell therapies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Recipient: Orca Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 02, 2020
Details:
This partnership brings together Lyell’s research and development of cell-based immunotherapies and Sarah Cannon’s expertise in designing and optimizing clinical trials to expand treatment options and access for patients.
Lead Product(s): CAR T-Cell therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Recipient: Sarah Cannon
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 27, 2020
Details:
The Company will use proceeds to advance its proprietary TCR-mimic and antibody-TCR ARTEMIS® programs, including Eureka’s anti-AFP ARTEMIS® Phase I/II clinical trial in the United States.
Lead Product(s): ET140202
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: Eureka Therapeutics
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Series E Financing March 17, 2020
Details:
The series A funding is to advance regulatory T cell therapy in autoimmune and degenerative diseases.
Lead Product(s): Treg therapy
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Recipient: Sonoma Biotherapeutics
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing February 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
